Cargando…

Antiangiogenic Compound Axitinib Demonstrates Low Toxicity and Antitumoral Effects against Medulloblastoma

SIMPLE SUMMARY: Medulloblastoma is the most frequent pediatric brain cancer. Despite great improvements in the treatment of this disease over the last decades, survivors are subject to debilitating adverse effects that strongly impair their quality of life. There is an urgent need to find efficient...

Descripción completa

Detalles Bibliográficos
Autores principales:	Pagnuzzi-Boncompagni, Marina, Picco, Vincent, Vial, Valérie, Planas-Bielsa, Victor, Vandenberghe, Ashaina, Daubon, Thomas, Derieppe, Marie-Alix, Montemagno, Christopher, Durivault, Jérôme, Grépin, Renaud, Martial, Sonia, Doyen, Jérôme, Gavard, Julie, Pagès, Gilles
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2021
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8750527/ https://www.ncbi.nlm.nih.gov/pubmed/35008234 http://dx.doi.org/10.3390/cancers14010070

Ejemplares similares

VEGFC negatively regulates the growth and aggressiveness of medulloblastoma cells
por: Penco-Campillo, Manon, et al.
Publicado: (2020)

Author Correction: VEGFC negatively regulates the growth and aggressiveness of medulloblastoma cells
por: Penco-Campillo, Manon, et al.
Publicado: (2020)

Neuropilin 1 and Neuropilin 2 gene invalidation or pharmacological inhibition reveals their relevance for the treatment of metastatic renal cell carcinoma
por: Dumond, Aurore, et al.
Publicado: (2021)

Inhibiting ALK2/ALK3 Signaling to Differentiate and Chemo-Sensitize Medulloblastoma
por: Filipponi, Doria, et al.
Publicado: (2022)

Targeting of the ELR+CXCL/CXCR1/2 Pathway Is a Relevant Strategy for the Treatment of Paediatric Medulloblastomas
por: Penco-Campillo, Manon, et al.
Publicado: (2022)

Inhibition of the amino‐acid transporter LAT1 demonstrates anti‐neoplastic activity in medulloblastoma
por: Cormerais, Yann, et al.
Publicado: (2019)

Axitinib Has Antiangiogenic and Antitumorigenic Activity in Myxoid Liposarcoma
por: Kerr, Lauren T., et al.
Publicado: (2016)

Anti-Vascular Endothelial Growth Factor C Antibodies Efficiently Inhibit the Growth of Experimental Clear Cell Renal Cell Carcinomas
por: Dumond, Aurore, et al.
Publicado: (2021)

AKT1 restricts the invasive capacity of head and neck carcinoma cells harboring a constitutively active PI3 kinase activity
por: Brolih, Sanja, et al.
Publicado: (2018)

Pancreatic Ductal Adenocarcinoma: The Dawn of the Era of Nuclear Medicine?
por: Montemagno, Christopher, et al.
Publicado: (2021)

In vivo monitoring of the therapeutic efficacy of a CXCR1/2 inhibitor with 18F-FDG PET/CT imaging in experimental head and neck carcinoma: A feasibility study
por: Montemagno, Christopher, et al.
Publicado: (2021)

Targeting the pro-angiogenic forms of VEGF or inhibiting their expression as anti-cancer strategies
por: Guyot, Mélanie, et al.
Publicado: (2016)

A group of novel VEGF splice variants as alternative therapeutic targets in renal cell carcinoma
por: Montemagno, Christopher, et al.
Publicado: (2023)

Angiogenesis and Lymphangiogenesis in Medulloblastoma Development
por: Penco-Campillo, Manon, et al.
Publicado: (2023)

The combination of bevacizumab/Avastin and erlotinib/Tarceva is relevant for the treatment of metastatic renal cell carcinoma: the role of a synonymous mutation of the EGFR receptor
por: Grépin, Renaud, et al.
Publicado: (2020)

Cytotoxic effects and tolerability of gemcitabine and axitinib in a xenograft model for c-myc amplified medulloblastoma
por: Schwinn, Stefanie, et al.
Publicado: (2021)

Antiangiogenic Therapy in the Treatment of Recurrent Medulloblastoma in the Adult: Case Report and Review of the Literature
por: Privitera, Giuseppe, et al.
Publicado: (2009)

Axitinib in the treatment of renal cell carcinoma: design, development, and place in therapy
por: Bellesoeur, Audrey, et al.
Publicado: (2017)

MBCL-43. RECURRENT MEDULLOBLASTOMA – LONG-TERM SURVIVAL WITH A “MEMMAT” BASED ANTIANGIOGENIC APPROACH
por: Slavc, Irene, et al.
Publicado: (2020)

MBCL-33. RARE PULMONARY TOXICITY IN THREE MEDULLOBLASTOMA PATIENTS UNDERGOING ANTIANGIOGENIC METRONOMIC COMBINATION THERAPY
por: Lenzen, Alicia, et al.
Publicado: (2020)

Sustained Survival Benefit in Recurrent Medulloblastoma by a Metronomic Antiangiogenic Regimen: A Nonrandomized Controlled Trial
por: Peyrl, Andreas, et al.
Publicado: (2023)

Antiangiogenic Properties of Axitinib versus Sorafenib Following Sunitinib Resistance in Human Endothelial Cells—A View towards Second Line Renal Cell Carcinoma Treatment
por: Juengel, Eva, et al.
Publicado: (2021)

Improved Long-Term Survival of Patients with Recurrent Medulloblastoma Treated with a “MEMMAT-like” Metronomic Antiangiogenic Approach
por: Slavc, Irene, et al.
Publicado: (2022)

Effects of ultraviolet radiation and nutrient level on the physiological response and organic matter release of the scleractinian coral Pocillopora damicornis following thermal stress
por: Courtial, Lucile, et al.
Publicado: (2018)

Selenium substituted axitinib reduces axitinib side effects and maintains its anti-renal tumor activity
por: Fu, Ying, et al.
Publicado: (2022)

Axitinib in Metastatic Renal Cell Carcinoma
por: Mittal, Kriti, et al.
Publicado: (2012)

ATLAS trial of adjuvant axitinib in patients with renal cell carcinoma: subgroup analyses with focus on axitinib dosing and racial groups
por: Quinn, D.I., et al.
Publicado: (2021)

Effect of ketoconazole on the pharmacokinetics of axitinib in healthy volunteers
por: Pithavala, Yazdi K., et al.
Publicado: (2010)

Axitinib for the Management of Metastatic Renal Cell Carcinoma
por: Escudier, Bernard, et al.
Publicado: (2012)

Axitinib: Newly Approved for Renal Cell Carcinoma
por: Tyler, Timothy
Publicado: (2012)

Design, Synthesis, and Biological Evaluation of Axitinib Derivatives
por: Wei, Na, et al.
Publicado: (2018)

Inhibition of Axitinib on Buspirone Metabolism in vitro and in vivo
por: Zhang, Bo-Wen, et al.
Publicado: (2022)

The FDA approved PI3K inhibitor GDC‐0941 enhances in vitro the anti‐neoplastic efficacy of Axitinib against c‐myc‐amplified high‐risk medulloblastoma
por: Ehrhardt, Michael, et al.
Publicado: (2018)

Integrin-αvβ3 as a Therapeutic Target in Glioblastoma: Back to the Future?
por: Echavidre, William, et al.
Publicado: (2022)

VEGFC acts as a double-edged sword in renal cell carcinoma aggressiveness
por: Ndiaye, Papa Diogop, et al.
Publicado: (2019)

Cost-effectiveness comparison of cabozantinib with everolimus, axitinib, and nivolumab in the treatment of advanced renal cell carcinoma following the failure of prior therapy in England
por: Meng, Jie, et al.
Publicado: (2018)

Antiangiogenic therapy
por: Avitabile, T
Publicado: (2010)

Genetic disruption of the pH(i)-regulating proteins Na(+)/H(+) exchanger 1 (SLC9A1) and carbonic anhydrase 9 severely reduces growth of colon cancer cells
por: Parks, Scott K., et al.
Publicado: (2016)

Influence of mild and moderate hepatic impairment on axitinib pharmacokinetics
por: Tortorici, Michael A., et al.
Publicado: (2010)

Axitinib Improves Radiotherapy in Murine Xenograft Lung Tumors
por: Hillman, Gilda G., et al.
Publicado: (2014)

Cannot write session to /tmp/vufind_sessions/sess_dsv38mjsp2rc36bihdra7evv4a